Hemostemix
Business Services · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
707-7th Ave SW Ste 1150, Calgary, Albert...Website
www.hemostemix.comRevenue
-Stock Symbol
HEMIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Hemostemix
Hemostemix Inc a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function.Explore more
Hemostemix Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Hemostemix your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Hemostemix is spiking on competitors!
Check if Hemostemix has recently received funding, and reach out quickly before it becomes old news!
Click to see if Hemostemix had a recent Job posting/layoffs
Earning: See what the market has to say on Hemostemix recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Hemostemix
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Hemostemix launches new products
Funding: Get notified immidiatlly once Hemostemix has new funding data
Website visits: Recent activity has been detected on your website
Hemostemix, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Hemostemix
Find 2 more new buyers
Compare Similar Companies to Hemostemix
Compare insights from companies similar to Hemostemix, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Hemostemix is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Hemostemix is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Hemostemix.
Hemostemix financials insights
Gather financial insights about Hemostemix, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$2.5M
Stock/Share Issuance
$342K
Hemostemix Tech Stack
A closer look at the technologies used by Hemostemix
Most Recent Scoops
Person-Based
Person-Based
Person-Based
Person-Based
Person-Based
Hemostemix News & Media
Hemostemix $1,000,000 Private Placement
Hemostemix Inc. Announces $1,000,000 non brokered private placement of up to 20 Million Units at $0.05 each. Hemostemix Inc. (OTCQB:HMTXF) CALGARY, ALBERTA, CANADA, May 21, 2026 /EINPresswire.com/ -- Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: …Hemostemix Secures $469,366 Private Placement Financing | HMTXF Stock News
Fresh capital injection of $469,366 through 3.9M shares at $0.12 each. Learn how Hemostemix plans to deploy funds for operational growth. Get complete details.Hemostemix Secures $2.5M Financing Deal Led by Company Chairman - Stock Titan
Chairman leads $1.5M private placement at $0.10 per unit, enabling full repayment of $2.5M debenture. Strategic move strengthens balance sheet. See investment details.Peripheral Arterial Disease (PAD) Pipeline Research Report 2024: Comprehensive Insights About 22+ Pipeline Drugs Featuring AdvanceCor, Novo Nordisk, Hemostemix, Helixmith, Aplagon, Vasa, IsomAb
Dublin, Nov. 21, 2024 (GLOBE NEWSWIRE) -- The "Peripheral Arterial Disease (PAD)- Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Hemostemix
Sign Up For FreeTo access detailed company insights
Hemostemix Inc a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as h... Read More
